Evidence map›Paper›PMID 39250756›Full record

ArticleClinical and experimental immunology2025

CpG oligodeoxynucleotide-coated chitosan nanoparticles enhance macrophage proinflammatory phenotype in vitro.

Fatemeh Karami, Hassan Namdar Ahmadabad, Marjan Shaheli

Abstract read
In one paragraph

Article in Clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fatemeh KaramiBiology, Arsanjan Branch, Azad University, Arsanjan, Iran.
Hassan Namdar AhmadabadVector-borne Diseases Research Center, North Khorasan University of Medical Science, Bojnurd, Iran.
Marjan ShaheliBiology, Arsanjan Branch, Azad University, Arsanjan, Iran.ORCID 0000-0003-2177-9642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the effects of CpG oligodeoxynucleotide (CpG-ODNs)-coated chitosan nanoparticles (CNP) on the phenotype of murine macrophages and their proinflammatory cytokine profile in vitro. CNP-CpG-ODNs loaded with FITC-scrambled siRNA were prepared using the ionotropic gelation method. Peritoneal macrophages were isolated and exposed to CNP-CpG-ODNs. Treated macrophages were assessed for uptake capacity. Flow cytometry was used to evaluate the expression levels of MHC-II, CD40, and CD86 costimulatory molecules in treated macrophages. Furthermore, the secretion levels of proinflammatory cytokines (TNF-α and IL-6) and the release of nitric oxide (NO) were measured in the culture supernatant of treated macrophages using sandwich ELISA and the Griess reaction, respectively. These in vitro studies showed that CNP-CpG-ODNs had no cytotoxic effect on macrophages and were efficiently taken up by them. Additionally, CNP-CpG-ODNs significantly increased the production of TNF-α, IL-6, and NO in the culture supernatant compared to CNP alone. Moreover, CNP-CpG-ODNs enhanced the expression of MHC-II, CD40, and CD86 costimulatory molecules on macrophages. These findings indicate that incorporating CpG-ODNs into CNPs promotes macrophage maturation and a proinflammatory phenotype. Therefore, CNP-CpG-ODNs may serve as an effective system for targeted gene delivery to macrophages, enhancing immune responses.

Indexed as

ChitosanMacrophages, PeritonealNanoparticlesOligodeoxyribonucleotidesAnimalsB7-2 AntigenCD40 AntigensCells, CulturedCytokinesHistocompatibility Antigens Class IIInterleukin-6MacrophagesMiceNitric OxidePhenotypeTumor Necrosis Factor-alphaB7-2 AntigenCD40 AntigensChitosanCPG-oligonucleotideCytokinesHistocompatibility Antigens Class IIInterleukin-6Nitric OxideOligodeoxyribonucleotidesTumor Necrosis Factor-alphachitosan nanoparticlesCpGimmune responsesmacrophage

Identifiers

PMID39250756
PMCPMC11754863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.